Aurinia Pharmaceuticals Inc
Research Aurinia Pharmaceuticals Inc (AUPH) on Bullrun: market cap USD 2.23B, P/E 7.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAUPH
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.23B
- P/E7.3
- Financial periodQ2 2026
- RevenueUSD 83.22M
- Net incomeUSD 37.41M
- Free cash flowUSD 52.57M
- Gross margin92.1%
Valuation Snapshot
latest market cap is USD 2.23B; P/E is 7.3.
Peer valuation comparison
Latest P/E is 7.32x versus a Healthcare sector median of 24.46x (70.1% below).
Latest P/E is 7.32x versus a Canada median of 15.58x (53.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 283.06M | USD 287.20M | USD 135.41M | 88.5% | 2.07 | USD 80.16M | USD 74.81M | USD 581.33M |
| FY2024 | USD 235.13M | USD 5.80M | USD 44.11M | 88.0% | 0.04 | USD 83.40M | USD 79.37M | USD 377.48M |
| FY2023 | USD 175.51M | -USD 78.00M | n/a | 91.9% | -0.54 | USD 48.76M | USD 97.61M | USD 377.95M |
| FY2022 | USD 134.03M | -USD 108.20M | n/a | 95.8% | -0.76 | USD 94.09M | USD 8.38M | USD 405.44M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.23B | 7.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.11B | 7.7 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.27B | 224.5 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.29B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 613.91M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 3.24B | n/a | n/a | n/a |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aurinia Pharmaceuticals Inc's market cap?
Aurinia Pharmaceuticals Inc's market capitalization is USD 2.23B.
What is Aurinia Pharmaceuticals Inc's P/E ratio?
Aurinia Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 7.3.
What does Aurinia Pharmaceuticals Inc do?
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.